Ceapro’s (TSXV:CZO) two bioprocessing plants in Alberta received a site license from the Health Canada Natural and Non-Prescription Health Products Directorate, which enables the company to fabricate, package, label, release and distribute final products.
“Receiving this is a further testament of the quality management system being implemented at Ceapro, which has also been recognized by major customers during their audits conducted at the end of 2018,” Gilles Gagnon, president and CEO, said in a statement.
He said issuance of this license is another important milestone in the transition of Ceapro’s business model from a contract manufacturer to a biopharmaceutical company.
“This license will enable us to not only produce and sell active ingredients as raw material, but will also allow Ceapro to manufacture and release its own finished products, such as beta glucan tablets and other PGX-processed new chemical entities,” he added.
